Page last updated: 2024-10-15

phosphoserine and Cardiomyopathy, Hypertrophic

phosphoserine has been researched along with Cardiomyopathy, Hypertrophic in 2 studies

Phosphoserine: The phosphoric acid ester of serine.

Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
O'Leary, TS1
Snyder, J1
Sadayappan, S1
Day, SM1
Previs, MJ1
Fu, Y1
Westenbroek, RE1
Scheuer, T1
Catterall, WA1

Other Studies

2 other studies available for phosphoserine and Cardiomyopathy, Hypertrophic

ArticleYear
MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
    Journal of molecular and cellular cardiology, 2019, Volume: 127

    Topics: Actin Cytoskeleton; Actomyosin; Adult; Alleles; Animals; Cardiomyopathy, Hypertrophic; Carrier Prote

2019
Basal and β-adrenergic regulation of the cardiac calcium channel CaV1.2 requires phosphorylation of serine 1700.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Nov-18, Volume: 111, Issue:46

    Topics: Adaptation, Physiological; Adrenergic beta-Agonists; Amino Acid Substitution; Animals; Arrhythmias,

2014